Mast Therapeutics, Inc. (MSTX)

[Blinkx90]

BTW, Roth just issued a a report from the SCD KOL(Key Opinion Leader) Dinner just held. Some real interesting KEY takeaways. Most notably about the % of patients on HU(Hydroxyurea). If you recall, in the 1st failed MST-118 trial, the rate on concurrent HU + MST-118 was just 21%, if that number had increased to 30%, despite all of the massive design trial probs etc, the result would have been VERY positive. (Patients on HU +MST-118 had time of crisis improved by 3x) According to Julie Kanter, who presented at Mast's SCD conf just held, 50% (FIFTY) of her SC patients were on HU. If you have the most BASIC of statistics knowledge and have looked at the failed trial results+the EPIC design, you will understand how HUGE this ONE piece of information is.

G/L
BlinkX90